Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2005-09-02
2009-08-25
Blanchard, David J. (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S326000, C435S069600, C435S007100, C530S387100, C530S388100, C424S130100, C424S138100, C424S141100
Reexamination Certificate
active
07579187
ABSTRACT:
The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
REFERENCES:
patent: 5160723 (1992-11-01), Welt et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5643550 (1997-07-01), Welt et al.
patent: 5958412 (1999-09-01), Welt et al.
patent: 6307026 (2001-10-01), King et al.
patent: 2002/0199213 (2002-12-01), Tomizuka et al.
patent: 200239422 (2004-05-01), None
patent: 1 306 706 (1986-04-01), None
patent: 1487996 (2004-05-01), None
patent: 120694 (1984-10-01), None
patent: 125023 (1984-11-01), None
patent: 0 199 141 (1986-10-01), None
patent: 1354034 (2004-05-01), None
patent: 2188638 (1987-10-01), None
patent: 200300651 (2004-05-01), None
patent: 62-111697 (1987-05-01), None
patent: 2004-515230 (2004-05-01), None
patent: 2004-259090 (2004-09-01), None
patent: 2003074634 (2004-05-01), None
patent: 2003004793 (2004-05-01), None
patent: WO 01/30393 (2001-05-01), None
patent: WO 02/43478 (2002-06-01), None
Kazuma Tomizuka et al., “Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and κ loci and expression of fully human antibodies”, PNAS, vol. 97, No. 2, Jan. 18, 2000, pp. 722-727.
Sydney Welt et al., “Preliminary Report of a Phase I Study of Combination Chemotherapy and Humanized A33 Antibody Immunotherapy in Patients with Advanced Colorectal Cancer”, Clinical Cancer Research, vol. 9, Apr. 2003, pp. 1347-1353.
Ando, et al.,Tan-Clone-Kotai-Jikken-Manual(“Experimental Manual for Monoclonal Antibody”) (written by and published by Kodansha Scientific, Ltd., Tokyo, Japan (1991).
Bruggemann, et al., “The Immunogenicity of Chimeric Antibodies”,J. Exp. Med., Dec. 1989, vol. 170, No. 6, pp. 2153-2157.
Delves, P. J., “Antibody Production Essential Techniques”,Monoclonal Antibodies, Ed. Shepherd and Dean, Oxford University Press, 2000.
Fishwild, et al., “High-avidity Human IgGκ Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,”Nat Biotechnol., Jul. 1996, vol. 14, No. 7, pp. 845-851.
Garin-Chesa, et al., “Organ-specific expression of the Colon Cancer Antigen A33, a Cell Surface Target for Antibody-based Therapy”,International J. Oncology, Sep. 1996, vol. 9, No. 3, pp. 465-471.
Goding, J. W.,Monoclonal Antibodies: Principles and Practice, Academic Press, 1993.
Green, L., “Antibody Engineering via Genetic Engineering of the Mouse; XenoMouse Strains are a Vehicle for the Facile Generation of Therapeutic Human Monoclonal Antibodies,”Journal of Immunological Methods, 1999, No. 231, pp. 11-23.
Ishida & Lonberg, IBC's 11th Antibody Engineering, Abstract 2000.
Janeway, et al.,Immunobiology, Current Biology Ltd/Garland Publishing Inc., 1997.
Katakura, et al., “Productivity Enhancement of Recombinant Protein in CHO Cells via Specific Promoter Activation by Oncogenes”,Cytotechnology, 1999, vol. 31, pp. 103-109.
Kearney, et al., “A New Mouce Myeloma Cell Line that has Lost Immunoglobulin Expression but Permits the Construction of Antibody-Secreting Hybrid Cell Lines”,J. Immunology, Sep. 1979, vol. 123, No. 3, pp. 1548-1550.
King, D.J.,Applications and Engineering of Monoclonal Antibodies, T. J. International Ltd, 1998.
King, et al., “Preparation of Preclinical Evaluation of Humanized A33 Immunoconjugates for Radioimmunotherapy”,British J. Cancer, Dec. 1995, vol. No. 6, pp. 1364-1372.
Kohler, et al., “Derivation of Specific Antibody-producing Tissue Culture and Tumor Lines by Cell Fusion”,European J. Immunology, 1966, vol. 6, pp. 511-519.
Margolin, et al., “Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination with Chemotherapy in Patients with Advanced Cancer: Pharmacologic and Long-Term Safety Data”,J. Clin. Oncol., Feb. 2001, vol. 19, No. 3, pp. 851-856.
Mark, et al., “Site-specific Mutagenesis of the Human Fibroblast Interferon Gene”,Proc Natl Acad Sci U.S.A., Sep. 1984, vol. 81, No. 18, pp. 5662-5666.
Matteucci and Caruthers, “Synthesis of Deoxyoligonucleotides on a Polymer Support”,J. Am. Chem. Soc., Jun. 1981. vol. 103, No. 11, pp. 3185-3191.
Riechmann, et al., “Reshaping Human Antibodies for Therapy”,Nature, Mar. 1988, vol. 332, No. 6162, pp. 323-327.
Schroff, et al., “Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy”,Canc. Res., Feb. 1985, vol. 45, No. 2, pp. 879-885.
Shulman, et al., “A Better Cell Line for Making Hybridomas Secreting Specific Antibodies”,Nature, Nov. 1978, vol. 276, No. 5685, pp. 269-270.
Tao, et al., “Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation”,J. Exp. Med, Aug. 1993, vol. 178, pp. 661-667.
Welt, et al., “Phase I Study of Anticolon Cancer Humanized Antibody A33”,Clinical Cancer Res., Apr. 2003, vol. 9, No. 4, pp. 1338-1346.
Welt, et al., “Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients with Advanced Colon Cancer”,J. Clinical Oncology, Aug. 1994, vol. 12, No. 8, pp. 1561-1571.
Welt, et al., “Phase I/II Study of Iodine 125-Labeled Monoclonal Antibody A33 in Patients with Advanced Colon Cancer”,J. Clinical Oncology, Jun. 1996, vol. 14, No. 6, pp. 1787-1797.
Wright, et al., “High Level Expression of Active Human Alpha-1-Antitrypsin in the Milk of Transgenic Sheep”,Bio/Technology, Jul. 1991, vol. 9, No. 7, pp. 830-834.
Yelton, et al. , “Fusion of Mouse Myeloma and Spleen Cells”,Current Topics in Microbiology and Immunology, 1978, vol. 81, pp. 1-7.
Supplementary European Search Report, EP 05778552 issued Feb. 26, 2009, 5 pages.
Rader, et al., “The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies”,J. Biol. Chem., May 5, 2000, vol. 275, No. 18, pp. 13668-13676.
Kataoka Shiro
Otani Noriko
Tomura Takafumi
Blanchard David J.
Foley & Lardner LLP
Gussow Anne M.
Kyoma Hakko Kirin Co., Ltd.
LandOfFree
Anti-A33 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-A33 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-A33 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115034